Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dal-OUTCOMES: Dalcetrapib in Recent ACS
NCT00658515Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2008
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and coronary heart disease (CHD) comparing Dalcetrapib with Placebo (2 arms). Primary endpoint: Incidence of Cardiovascular Mortality and Morbidity at 48 months. Started Apr 2008; status: completed.
02
Drugs
dalcetrapib
03
Conditions
acute coronary syndrome (ACS)coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT00658515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658515.